866-997-4948(US-Canada Toll Free)

Pigmented Villonodular Synovitis - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 45 Pages

Pigmented Villonodular Synovitis - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pigmented Villonodular Synovitis - Pipeline Review, H2 2017, provides an overview of the Pigmented Villonodular Synovitis (Musculoskeletal Disorders) pipeline landscape.

Pigmented villonodular synovitis (PVNS) is a condition that causes the synovium. PVNS is characterized by inflammation and overgrowth of the joint lining. This affects the hip or knee. Symptoms include pain, swelling in the affected joint, locking, catching, and instability in the joint. Treatment includes surgery and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pigmented Villonodular Synovitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pigmented Villonodular Synovitis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pigmented Villonodular Synovitis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Pigmented Villonodular Synovitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 1, 3 and 2 respectively.

Pigmented Villonodular Synovitis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pigmented Villonodular Synovitis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Pigmented Villonodular Synovitis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pigmented Villonodular Synovitis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pigmented Villonodular Synovitis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pigmented Villonodular Synovitis (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pigmented Villonodular Synovitis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pigmented Villonodular Synovitis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Pigmented Villonodular Synovitis - Overview 5
Pigmented Villonodular Synovitis - Therapeutics Development 6
Pipeline Overview 6
Pipeline by Companies 7
Products under Development by Companies 8
Pigmented Villonodular Synovitis - Therapeutics Assessment 9
Assessment by Target 9
Assessment by Mechanism of Action 11
Assessment by Route of Administration 13
Assessment by Molecule Type 15
Pigmented Villonodular Synovitis - Companies Involved in Therapeutics Development 17
Bristol-Myers Squibb Co 17
F. Hoffmann-La Roche Ltd 17
Novartis AG 18
Plexxikon Inc 18
Pigmented Villonodular Synovitis - Drug Profiles 19
cabiralizumab - Drug Profile 19
Product Description 19
Mechanism Of Action 19
R&D Progress 19
emactuzumab - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
MCS-110 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
nilotinib - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
pexidartinib hydrochloride - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
PLX-73086 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Pigmented Villonodular Synovitis - Product Development Milestones 41
Featured News & Press Releases 41
Jun 01, 2014: Roche to present phase I data on investigational cancer immunotherapy anti-CSF-1R (RG7155) antibody in patients with Pigmented Villonodular Synovitis 41
May 14, 2014: Plexxikon Announces PLX3397 Data Presentations at ASCO 2014 Annual Meeting 42
May 14, 2014: Plexxikon Announces Promising Preliminary PLX3397 Phase 1 Extension Data in Patients with Pigmented Villonodular Synovitis 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 44
Disclaimer 45

List of Tables
Number of Products under Development for Pigmented Villonodular Synovitis, H2 2017 6
Number of Products under Development by Companies, H2 2017 7
Products under Development by Companies, H2 2017 8
Number of Products by Stage and Target, H2 2017 10
Number of Products by Stage and Mechanism of Action, H2 2017 12
Number of Products by Stage and Route of Administration, H2 2017 14
Number of Products by Stage and Molecule Type, H2 2017 16
Pigmented Villonodular Synovitis - Pipeline by Bristol-Myers Squibb Co, H2 2017 17
Pigmented Villonodular Synovitis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 17
Pigmented Villonodular Synovitis - Pipeline by Novartis AG, H2 2017 18
Pigmented Villonodular Synovitis - Pipeline by Plexxikon Inc, H2 2017 18

List of Figures
Number of Products under Development for Pigmented Villonodular Synovitis, H2 2017 6
Number of Products under Development by Companies, H2 2017 7
Number of Products by Targets, H2 2017 9
Number of Products by Stage and Targets, H2 2017 9
Number of Products by Mechanism of Actions, H2 2017 11
Number of Products by Stage and Mechanism of Actions, H2 2017 11
Number of Products by Routes of Administration, H2 2017 13
Number of Products by Stage and Routes of Administration, H2 2017 13
Number of Products by Molecule Types, H2 2017 15
Number of Products by Stage and Molecule Types, H2 2017 15

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *